Antacids Market

Antacids Market (Drug Class - Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers; Formulation Type - Tablet, Liquid, and Powder; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL32864
  • Published On : Oct 2017
  • No. of Pages : 184
  • Category : Pharmaceutical

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Antacids Market

4. Market Overview
      4.1. Introduction
              4.1.1. Product Definition
              4.1.2. Industry Evolution / Developments
      4.2. Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunity
      4.4. Global Antacids Market Value (US$ Mn) Forecast, 2017 - 2025
      4.5. Porter’s Five Force Analysis
      4.6. Value Chain Analysis
      4.7. Market Outlook

5. Global Antacids Market Analysis and Forecasts, By Drug Class 
      5.1. Introduction & Definition
      5.2. Key Findings / Developments
      5.3. Key Trends
      5.4. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              5.4.1. Proton pump inhibitors
              5.4.2. H2 Antagonist
              5.4.3. Acid neutralizers
      5.5. Market Attractiveness By Drug Class 

6. Global Antacids Market Analysis and Forecasts, By Formulation Type 
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Key Trends
      6.4. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              6.4.1. Tablet
              6.4.2. Liquid
              6.4.3. Powder
              6.4.4. Others
      6.5. Market Attractiveness By Formulation Type 

7. Global Antacids Market Analysis and Forecasts, By Distribution Channel 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Key Trends      
      7.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              7.4.1. Hospital Pharmacies
              7.4.2. Retail Pharmacies
              7.4.3. Others
      7.5. Market Attractiveness By Distribution Channel 

8. Global Antacids Market Analysis and Forecasts, By Region
      8.1. Key Findings
      8.2. Market Value (US$ Mn) Forecast, By Region, 2017-2025
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Asia Pacific 
              8.2.4. Latin America 
              8.2.5. Middle East and Africa 
      8.3. Market Attractiveness By Region

9. North America Antacids Market Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
              9.1.2. Key Trends
      9.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              9.2.1. Proton pump inhibitors
              9.2.2. H2 Antagonist
              9.2.3. Acid neutralizers
      9.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              9.3.1. Tablet
              9.3.2. Liquid
              9.3.3. Powder
              9.3.4. Others
      9.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              9.4.1. Hospital Pharmacies
              9.4.2. Retail Pharmacies
              9.4.3. Others
      9.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
              9.5.1. U.S.
              9.5.2. Canada
      9.6. Market Attractiveness Analysis 
              9.6.1. By Drug Class 
              9.6.2. By Formulation Type 
              9.6.3. By Distribution Channel 
              9.6.4. By Country

10. Europe Antacids Market Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
              10.1.2. Key Trends
      10.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              10.2.1. Proton pump inhibitors
              10.2.2. H2 Antagonist
              10.2.3. Acid neutralizers
      10.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              10.3.1. Tablet
              10.3.2. Liquid
              10.3.3. Powder
              10.3.4. Others
      10.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              10.4.1. Hospital Pharmacies
              10.4.2. Retail Pharmacies
              10.4.3. Others
      10.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
              10.5.1. U.K.
              10.5.2. Germany
              10.5.3. France 
              10.5.4. Spain
              10.5.5. Italy
              10.5.6. Rest of Europe
      10.6. Market Attractiveness Analysis 
              10.6.1. By Drug Class 
              10.6.2. By Formulation Type 
              10.6.3. By Distribution Channel 
              10.6.4. By Country

11. Asia Pacific Antacids Market Analysis and Forecast
      11.1. Introduction
              11.1.1. Key Findings
              11.1.2. Key Trends
      11.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              11.2.1. Proton pump inhibitors
              11.2.2. H2 Antagonist
              11.2.3. Acid neutralizers
      11.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              11.3.1. Tablet
              11.3.2. Liquid
              11.3.3. Powder
              11.3.4. Others
      11.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              11.4.1. Hospital Pharmacies
              11.4.2. Retail Pharmacies
              11.4.3. Others
      11.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
              11.5.1. India 
              11.5.2. China
              11.5.3. Japan
              11.5.4. Australia & New Zealand 
              11.5.5. Rest of Asia Pacific
      11.6. Market Attractiveness Analysis 
              11.6.1. By Drug Class 
              11.6.2. By Formulation Type 
              11.6.3. By Distribution Channel 
              11.6.4. By Country

12. Latin America Antacids Market Analysis and Forecast
      12.1. Introduction
              12.1.1. Key Findings
              12.1.2. Key Trends
      12.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              12.2.1. Proton pump inhibitors
              12.2.2. H2 Antagonist
              12.2.3. Acid neutralizers
      12.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              12.3.1. Tablet
              12.3.2. Liquid
              12.3.3. Powder
              12.3.4. Others
      12.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              12.4.1. Hospital Pharmacies
              12.4.2. Retail Pharmacies
              12.4.3. Others
      12.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
              12.5.1. Brazil 
              12.5.2. Mexico 
              12.5.3. Rest of Latin America      
      12.6. Market Attractiveness Analysis 
              12.6.1. By Drug Class 
              12.6.2. By Formulation Type 
              12.6.3. By Distribution Channel 
              12.6.4. By Country

13. Middle East and Africa Antacids Market Analysis and Forecast
      13.1. Introduction
              13.1.1. Key Findings
              13.1.2. Key Trends
      13.2. Market Value (US$ Mn) Forecast, By Drug Class, 2017–2025
              13.2.1. Proton pump inhibitors
              13.2.2. H2 Antagonist
              13.2.3. Acid neutralizers
      13.3. Market Value (US$ Mn) Forecast, By Formulation Type, 2017–2025
              13.3.1. Tablet
              13.3.2. Liquid
              13.3.3. Powder
              13.3.4. Others
      13.4. Market Value (US$ Mn) Forecast, By Distribution Channel, 2017–2025
              13.4.1. Hospital Pharmacies
              13.4.2. Retail Pharmacies
              13.4.3. Others
      13.5. Market Value (US$ Mn) Forecast, By Country, 2017–2025
              13.5.1. South Africa 
              13.5.2. Saudi Arabia 
              13.5.3. Rest of MEA
      13.6. Market Attractiveness Analysis 
              13.6.1. By Drug Class 
              13.6.2. By Formulation Type 
              13.6.3. By Distribution Channel 
              13.6.4. By Country

14. Competition Landscape
      14.1. Market Players
      14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
              14.2.1. AstraZeneca
                         14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.1.2. Business Overview
                         14.2.1.3. Product Portfolio 
                         14.2.1.4. Financial Overview 
                         14.2.1.5. SWOT Analysis 
                         14.2.1.6. Strategic overview
              14.2.2. Bayer AG 
                         14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.2.2. Business Overview
                         14.2.2.3. Product Portfolio 
                         14.2.2.4. Financial Overview 
                         14.2.2.5. SWOT Analysis 
                         14.2.2.6. Strategic overview
              14.2.3. Boehringer Ingelheim GmbH
                         14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.3.2. Business Overview
                         14.2.3.3. Product Portfolio 
                         14.2.3.4. Financial Overview 
                         14.2.3.5. SWOT Analysis 
                         14.2.3.6. Strategic overview 
              14.2.4. Dr. Reddy’s Laboratories Ltd.
                         14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.4.2. Business Overview
                         14.2.4.3. Product Portfolio 
                         14.2.4.4. Financial Overview 
                         14.2.4.5. SWOT Analysis 
                         14.2.4.6. Strategic overview
              14.2.5. GlaxoSmithKline plc
                         14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.5.2. Business Overview
                         14.2.5.3. Product Portfolio 
                         14.2.5.4. Financial Overview 
                         14.2.5.5. SWOT Analysis 
                         14.2.5.6. Strategic overview
              14.2.6. Johnson & Johnson
                         14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.6.2. Business Overview
                         14.2.6.3. Product Portfolio 
                         14.2.6.4. Financial Overview 
                         14.2.6.5. SWOT Analysis 
                         14.2.6.6. Strategic overview 
              14.2.7. Pfizer Inc. 
                         14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.7.2. Business Overview
                         14.2.7.3. Product Portfolio 
                         14.2.7.4. Financial Overview 
                         14.2.7.5. SWOT Analysis 
                         14.2.7.6. Strategic overview
              14.2.8. Procter & Gamble
                         14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.8.2. Business Overview
                         14.2.8.3. Product Portfolio 
                         14.2.8.4. Financial Overview 
                         14.2.8.5. SWOT Analysis 
                         14.2.8.6. Strategic overview
              14.2.9. Reckitt Benckiser Group plc
                         14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.9.2. Business Overview
                         14.2.9.3. Product Portfolio 
                         14.2.9.4. Financial Overview 
                         14.2.9.5. SWOT Analysis 
                         14.2.9.6. Strategic overview
              14.2.10. Sanofi
                         14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.10.2. Business Overview
                         14.2.10.3. Product Portfolio 
                         14.2.10.4. Financial Overview 
                         14.2.10.5. SWOT Analysis 
                         14.2.10.6. Strategic overview
              14.2.11. Sun Pharmaceuticals Ltd
                         14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.11.2. Business Overview
                         14.2.11.3. Product Portfolio 
                         14.2.11.4. Financial Overview 
                         14.2.11.5. SWOT Analysis 
                         14.2.11.6. Strategic overview 
              14.2.12. Takeda Pharmaceutical
                         14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.12.2. Business Overview
                         14.2.12.3. Product Portfolio 
                         14.2.12.4. Financial Overview 
                         14.2.12.5. SWOT Analysis 
                         14.2.12.6. Strategic overview
              14.2.13. Valeant Pharmaceuticals International, Inc.
                         14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.13.2. Business Overview
                         14.2.13.3. Product Portfolio 
                         14.2.13.4. Financial Overview 
                         14.2.13.5. SWOT Analysis 
                         14.2.13.6. Strategic overview

List of Tables

Table 01: Global Antacids Market Size (US$ Mn) Forecast, By Drug Class, 2015–2025
Table 02: Global Antacids Market Size (US$ Mn) Forecast, By Formulation Type, 2017–2025
Table 03: Global Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 04: Global Antacids Market (US$ Mn) Forecast, By Region, 2015–2025
Table 05: North America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 06: North America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 07: North America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 08: North America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 09: Europe Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 10: Europe Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 11: Europe Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 12: Europe Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 13: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 14: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 15: Asia Pacific Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 16: Asia Pacific Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Latin America Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 18: Latin America Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 19: Latin America Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015–2025
Table 20: Latin America Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 21: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 22: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Formulation Type, 2015–2025
Table 23: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, By Distribution Channel, 2015 and 2025
Table 24: Middle East and Africa Antacids Market Size (US$ Mn) Forecast, by Country, 2015–2025

List of Figures

Figure 01: Global Antacids Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, By Drug Class (2016)
Figure 03: Market Value Share, By Formulation Type (2016)
Figure 04: Market Value Share By, Distribution Channel (2016)
Figure 05: Market Value Share, By Region (2016)
Figure 06: Porter’s Five Force Analysis
Figure 07: Global Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 08: Global Proton Pump Inhibitor Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 09: Global H2 Antagonist Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global Acid Neutralizer Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Antacids Market Attractiveness Analysis, By Drug Class
Figure 12: Global Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 13: Global Antacids Tablet Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Antacids Liquids Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Antacids Powder Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 17: Global Antacids Market Attractiveness Analysis, By Formulation Type
Figure 18: Global Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 19: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 20: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 21: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 22: Global Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 23: Global Antacids Market Value Share, By Region, 2017 and 2025
Figure 24: Global Antacids Market Attractiveness Analysis, By Region Type
Figure 25: North America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 26: North America Antacids Market Attractiveness Analysis, By Country
Figure 27: North America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 28: North America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 29: North America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 30: North America Market Value Share Analysis, By Country, 2016 and 2025
Figure 31: North America Antacids Market Attractiveness Analysis, By Drug Class
Figure 32: North America Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 33: North America Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 34: Europe Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 35: Europe Antacids Market Attractiveness Analysis, By Country
Figure 36: Europe Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 37: Europe Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 38: Europe Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 39: Europe Market Value Share Analysis, By Country, 2016 and 2025
Figure 40: Europe Antacids Market Attractiveness Analysis, By Drug Class
Figure 41: Europe Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 42: Europe Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 43: Asia Pacific Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 44: Asia Pacific Antacids Market Attractiveness Analysis, By Country
Figure 45: Asia Pacific Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 46: Asia Pacific Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 47: Asia Pacific Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 48: Asia Pacific Market Value Share Analysis, By Country, 2016 and 2024
Figure 49: Asia Pacific Antacids Market Attractiveness Analysis, By Drug Class
Figure 50: Asia Pacific Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 51: Asia Pacific Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 52: Latin America Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 53: Latin America Antacids Market Attractiveness Analysis, By Country
Figure 54: Latin America Antacids Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 55: Latin America Antacids Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 56: Latin America Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 57: Latin America Market Value Share Analysis, By Country, 2016 and 2024
Figure 58: Latin America Antacids Market Attractiveness Analysis, By Drug Class
Figure 59: Latin America Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 60: Latin America Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 61: Middle East and Africa Antacids Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 62: Middle East and Africa Antacids Market Attractiveness Analysis, By Country
Figure 63: Middle East and Africa Market Value Share Analysis, By Drug Class, 2016 and 2025
Figure 64: Middle East and Africa Market Value Share Analysis, By Formulation Type, 2016 and 2025
Figure 65: Middle East and Africa Antacids Market Value Share Analysis, By Distribution Channel, 2016 and 2025
Figure 66: Middle East and Africa Market Value Share Analysis, By Country, 2016 and 2025
Figure 67: Middle East and Africa Antacids Market Attractiveness Analysis, By Drug Class
Figure 68: Middle East and Africa Antacids Market Attractiveness Analysis, By Formulation Type 
Figure 69: Middle East and Africa Antacids Market Attractiveness Analysis, By Distribution Channel
Figure 70: AstraZeneca, Breakdown of Net Sales (%), by Region, 2016
Figure 71: AstraZeneca, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 72: Bayer AG, Breakdown of Net Sales (%), by Region, 2016
Figure 73: Bayer AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 74: Boehringer Ingelheim, Break down of Net Sales (%), by Region, 2016
Figure 75: Boehringer Ingelheim, Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 76: Dr. Reddy’s, Breakdown of Net Sales (%), by Region, 2016
Figure 77: Dr. Reddy’s, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 78: GlaxoSmithKline, Breakdown of Net Sales (%), by Region, 2016
Figure 79: GlaxoSmithKline, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 80: Johnson & Johnson, Break down of Net Sales (%), by Region, 2016
Figure 81: Johnson & Johnson, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
Figure 82: Pfizer Inc., Breakdown of Net Sales (%), by Region, 2016 (%)
Figure 83: Pfizer Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 84: P&G, Breakdown of Net Sales (%), by Region, 2016
Figure 85: P&G, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 86: Reckitt Benckiser, Breakdown of Net Sales (%), by Region, 2016
Figure 87: Reckitt Benckiser, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 88: Sanofi, Breakdown of Net Sales (%), by Region, 2016
Figure 89: Sanofi, Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 90: Breakdown of Net Sales (%), by Region, 2016
Figure 91: Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 92: Takeda Pharmaceutical, Break down of Net Sales (%), by Region, 2016
Figure 93: Takeda Pharmaceutical, Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 94: Valeant Pharmaceuticals International, Inc., Break down of Net Sales (%), by Region, 2016
Figure 95: Valeant Pharmaceuticals International, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016

.